TCM
ANAB icon

TCG Crossover Management’s AnaptysBio ANAB Stock Holding History

TCG Crossover Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-58,515
Closed -$1.19M – 22
2022
Q2 		$1.19M Hold
58,515
– – 0.5% 20
2022
Q1 		$1.45M Buy
+58,515
New +$1.77M 0.58% 19

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

TCG Crossover Management's ANAB Position: Q3 2022 in Review

TCG Crossover Management sold out of AnaptysBio (ANAB) in Q3 2022, closing a stake of 58,515 shares — an estimated $1.19M sold.

TCG Crossover Management first reported a position in ANAB in Q1 2022 and held it in 2 quarters. The position peaked at $1.45M in Q1 2022. 114 funds tracked by Wall St. Rank hold ANAB as of Q3 2022.

  • TCG Crossover Management reported no remaining AnaptysBio position as of Q3 2022 after selling out during the quarter.
  • TCG Crossover Management sold 58,515 AnaptysBio shares in Q3 2022, an estimated $1.19M.
  • TCG Crossover Management first reported a position in AnaptysBio in Q1 2022 and held it in 2 quarters.
  • TCG Crossover Management's AnaptysBio position peaked at $1.45M in Q1 2022.
  • 114 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2022.

Based on TCG Crossover Management's 13F filing for Q3 2022, filed 14 Nov 2022.